Search

Your search keyword '"Rollier, Christine S."' showing total 201 results

Search Constraints

Start Over You searched for: Author "Rollier, Christine S." Remove constraint Author: "Rollier, Christine S." Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
201 results on '"Rollier, Christine S."'

Search Results

3. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison

6. An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease

7. Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine

9. Immunisation with purified Coxiella burnetii phase I lipopolysaccharide confers partial protection in mice independently of co-administered adenovirus vectored vaccines

10. Natural mutations in a Staphylococcus aureus virulence regulator attenuate cytotoxicity but permit bacteremia and abscess formation

16. Optimization of Zika virus envelope protein production for ELISA and correlation of antibody titers with virus neutralization in Mexican patients from an arbovirus endemic region

17. Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisation

19. Viral vectors expressing group B meningococcal outer membrane proteins induce strong antibody responses but fail to induce functional bactericidal activity

20. A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

22. Additional file 16 of Inclusion of a dual signal sequence enhances the immunogenicity of a novel viral vectored vaccine against the capsular group B meningococcus

24. Human B Cell Responses to Dominant and Subdominant Antigens Induced by a Meningococcal Outer Membrane Vesicle Vaccine in a Phase I Trial

25. Adenovirus vectors activate Vδ2 + γδT cells in a type I interferon‐, TNF‐, and IL‐18‐dependent manner

28. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

31. MAIT cell activation augments adenovirus vector vaccine immunogenicity

32. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

34. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

37. Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity

38. Activation of MAIT cells plays a critical role in viral vector vaccine immunogenicity

40. Adenovirus vectors activate Vδ2+ γδT cells in a type I interferon‐, TNF‐, and IL‐18‐dependent manner.

42. Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine.

44. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

50. Impact of Reducing Complement Inhibitor Binding on the Immunogenicity of Native Neisseria meningitidis Outer Membrane Vesicles

Catalog

Books, media, physical & digital resources